Zobrazeno 1 - 10
of 37
pro vyhledávání: '"John P M Finberg"'
Autor:
Stav Kemeny, Dikla Dery, Yelena Loboda, Marshall Rovner, Tali Lev, Dotan Zuri, John P M Finberg, Sarit Larisch
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e38837 (2012)
Parkinson's disease (PD) is associated with excessive cell death causing selective loss of dopaminergic neurons. Dysfunction of the Ubiquitin Proteasome System (UPS) is associated with the pathophysiology of PD. Mutations in Parkin which impair its E
Externí odkaz:
https://doaj.org/article/69ad29b6430a4995b84f2c17c98c66f8
Autor:
Moshe Gavish, John P M Finberg, Abraham Weizman, D. Offen, Yelena Loboda, Hadar Segal-Gavish, Yael Barhum, Martin Gabay, Avishai Gavish, Meygal Kahana, Nahum Allon
Publikováno v:
Molecular Psychiatry. 26:2626-2632
Delivery of drugs into the brain is poor due to the blood brain barrier (BBB). This study describes the development of a novel liposome-based brain-targeting drug delivery system. The liposomes incorporate a diacylglycerol moiety coupled through a li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a087c1c9e27d444b641270c8809414c
https://doi.org/10.1038/s41380-020-0742-4
https://doi.org/10.1038/s41380-020-0742-4
Autor:
John P M Finberg
Publikováno v:
Journal of Neural Transmission. 127:125-130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18f88d5ca60504c73985ebe65ac4a4ae
https://doi.org/10.1007/s00702-020-02142-w
https://doi.org/10.1007/s00702-020-02142-w
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease
Autor:
John P M Finberg
Publikováno v:
Journal of neural transmission (Vienna, Austria : 1996). 126(4)
MAO-B and COMT are both enzymes involved in dopamine breakdown and metabolism. Inhibitors of these enzymes are used in the treatment of Parkinson’s disease. This review article describes the scientific background to the localization and function of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e22cf61c4dc5b506ef4872b4dc5d98c
https://pubmed.ncbi.nlm.nih.gov/30386930
https://pubmed.ncbi.nlm.nih.gov/30386930
Publikováno v:
British Journal of Pharmacology. 170:999-1013
Background and Purpose Selective MAO type B (MAO-B) inhibitors are effective in potentiation of the clinical effect of L-DOPA in Parkinson's disease, but dopamine (DA) is deaminated mainly by MAO type A (MAO-A) in rat brain. We sought to clarify the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60514d31a675192d0d7fe396a8fa9054
https://doi.org/10.1111/bph.12349
https://doi.org/10.1111/bph.12349
Publikováno v:
Neuropharmacology. 48:406-416
Rasagiline (N-propargyl-1-R-aminoindan) is a new selective inhibitor of MAO-B which is in development for the treatment of Parkinson's disease. The aim of the present study was to evaluate the neuroprotective properties of rasagiline and characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce39b307bb27f90cd65c40d065ab22b9
https://doi.org/10.1016/j.neuropharm.2004.10.016
https://doi.org/10.1016/j.neuropharm.2004.10.016
Autor:
John P M Finberg, Lior Dayan
Publikováno v:
Neuropharmacology. 45:524-533
The ability of L-3,4-dihydroxyphenylalanine (L-DOPA) to release noradrenaline (NA) from peripheral and CNS neurons was studied using isolated rat vas deferens and in vivo frontal cortex microdialysis. Application of L-DOPA (30 microM) to vas deferens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36ce1dddf5268a7fd87186060422ad7
https://doi.org/10.1016/s0028-3908(03)00190-4
https://doi.org/10.1016/s0028-3908(03)00190-4
Publikováno v:
Journal of Neurochemistry. 67:1532-1539
Acute inhibition of monoamine oxidase B (MAO-B) in the rat does not affect striatal dopamine (DA) metabolism, but chronic MAO-B inhibition with deprenyl has been reported to increase the release of striatal DA, as shown using in vitro techniques. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c302103cac85849a18bee991e7d223
https://doi.org/10.1046/j.1471-4159.1996.67041532.x
https://doi.org/10.1046/j.1471-4159.1996.67041532.x
Autor:
Tamar Goren, Andras Zekany, Marta Weinstock, David Lerner, Jeffrey Sterling, Adela Zagyva, Istvan Miskolczi, Gila Lavian, Aviva Gross, Gyorgy Toth, Willy Goldenberg, John P M Finberg, Boris Krais, Yaacov Herzig, Tivadar Tamas, Michal Razin, Sandor Molnar, Nina Finkelstein, Ferenc Rantal, Rachel Friedman, Wei E. Huang, Moussa B.H. Youdim, Michael Chorev
Publikováno v:
Journal of Medicinal Chemistry. 45:5260-5279
Carbamate derivatives of N-propargylaminoindans (Series I) and N-propargylphenethylamines (Series II) were synthesized via multistep procedures from the corresponding hydroxy precursors. The respective rasagiline- and selegiline-related series were d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc1ba7d985a8f9d7b5a03c10ceb42d2e
https://doi.org/10.1021/jm020120c
https://doi.org/10.1021/jm020120c
Publikováno v:
British Journal of Pharmacology. 132:500-506
Rasagiline [N-propargyl-1R(+)-aminoindan], was examined for its monoamine oxidase (MAO) A and B inhibitor activities in rats together with its S(−)-enantiomer (TVP 1022) and the racemic compound (AGN-1135) and compared to selegiline (1-deprenyl). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f809350d58141ded9acb7351fca7210
https://doi.org/10.1038/sj.bjp.0703826
https://doi.org/10.1038/sj.bjp.0703826